Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Zhang, N P ^a,b   Reijnders, J G P ^a   Perquin, M ^a   Hansen, B E ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FUDAN UNIVERSITY   (China)

Author keywords

compliance; decompensation; resistance; sustained remission

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC LIVER DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; GENETIC RESISTANCE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 79959591362     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01448.x     Document Type: Article

References (31)

1. Lok ASF, Lai C-L,. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: incidence, predisposing factors and etiology. J Hepatol 1990; 10 (1): 29-34. (Pubitemid 20006985)
2. Perrillo RP,. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120 (4): 1009-1022. (Pubitemid 32193199)
3. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS,. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84 (2): 216-219. (Pubitemid 13224257)
4. Liaw YF, Tai DI, Chu CM, Chen TJ,. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8 (3): 493-496.
5. Liaw YF, Yang SS, Chen TJ, Chu CM,. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. J Hepatol 1985; 1 (3): 227-233.
6. Tsubota A, Arase Y, Suzuki Y, et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology 2004; 47 (6): 335-341. (Pubitemid 39541280)
7. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2): 335-352.
8. Alexander GJ, Brahm J, Fagan EA, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2 (8550): 66-69.
9. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323 (5): 295-301. (Pubitemid 20237094)
10. Peters M, Davis GL, Dooley JS, Hoofnagle JH,. The interferon system in acute and chronic viral hepatitis. Prog Liver Dis 1986; 8: 453-467.
11. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54 (11): 1604-1609. (Pubitemid 41531780)
12. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19 (11): 1276-1282.
13. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341 (17): 1256-1263. (Pubitemid 29489740)
14. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339 (2): 61-68. (Pubitemid 28304879)
15. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125 (6): 1714-1722. (Pubitemid 37500436)
16. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12 (8): 1295-1303.
17. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM,. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30 (2): 567-572.
18. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW,. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32 (3): 635-639.
19. Honkoop P, de Man RA, Heijtink RA, Schalm SW,. Hepatitis B reactivation after lamivudine. Lancet 1995; 346 (8983): 1156-1157.
20. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R,. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51 (4): 597-599.
21. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG,. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38 (8): 2897-2901. (Pubitemid 30640570)
22. Pas SD, Niesters HG,. Detection of HBV DNA using real time analysis. J Clin Virol 2002; 25 (1): 93-94. (Pubitemid 34765766)
23. van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG,. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003; 41 (2): 576-580. (Pubitemid 36184164)
24. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45 (2): 507-539. (Pubitemid 46374607)
25. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M,. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103 (5): 1630-1635.
26. Frome EL, Checkoway H,. Epidemiologic programs for computers and calculators. Use of Poisson regression models in estimating incidence rates and ratios. Am J Epidemiol 1985; 121 (2): 309-323. (Pubitemid 15158542)
27. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ,. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7 (1): 20-23.
28. Buster EHCJ, Flink HJ, Hansen BE, Janssen HLA,. Withdrawal flares after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg-positive chronic hepatitis B. J Hepatol 2007; 46 (Suppl. 1): A488.
29. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
30. Snow A, Sorbel J, Chappell B, Curtis M, Zhu Y, Borroto-Esoda K,. Lack of tenofovir DF (TDF) resistance mutations in treatment-naive and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF monotherapy. EASL conference Hepatitis B and C virus: resistance to antiviral therapy; Paris, France, 2008.
31. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49 (5): 1503-1514.